Clinical  ||| S:0 E:9 ||| JJ
presentations  ||| S:9 E:23 ||| NNS
and  ||| S:23 E:27 ||| CC
classification  ||| S:27 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
rosacea  ||| S:45 E:53 ||| JJ
Rosacea  ||| S:53 E:61 ||| NNP
is  ||| S:61 E:64 ||| VBZ
a  ||| S:64 E:66 ||| DT
chronic  ||| S:66 E:74 ||| JJ
skin  ||| S:74 E:79 ||| NN
disease  ||| S:79 E:87 ||| NN
affecting  ||| S:87 E:97 ||| VBG
up  ||| S:97 E:100 ||| RP
to  ||| S:100 E:103 ||| TO
10 ||| S:103 E:105 ||| CD
%  ||| S:105 E:107 ||| NN
of  ||| S:107 E:110 ||| IN
the  ||| S:110 E:114 ||| DT
population  ||| S:114 E:125 ||| NN
in  ||| S:125 E:128 ||| IN
some  ||| S:128 E:133 ||| DT
European  ||| S:133 E:142 ||| JJ
countries ||| S:142 E:151 ||| NNS
.  ||| S:151 E:153 ||| .
Rosacea  ||| S:153 E:161 ||| JJ
manifests  ||| S:161 E:171 ||| NN
as  ||| S:171 E:174 ||| IN
various  ||| S:174 E:182 ||| JJ
combinations  ||| S:182 E:195 ||| NNS
of  ||| S:195 E:198 ||| IN
characteristic  ||| S:198 E:213 ||| JJ
signs  ||| S:213 E:219 ||| NNS
and  ||| S:219 E:223 ||| CC
symptoms  ||| S:223 E:232 ||| NNS
in  ||| S:232 E:235 ||| IN
a  ||| S:235 E:237 ||| DT
centrofacial  ||| S:237 E:250 ||| JJ
distribution ||| S:250 E:262 ||| NN
.  ||| S:262 E:264 ||| .
At  ||| S:264 E:267 ||| IN
present ||| S:267 E:274 ||| JJ
,  ||| S:274 E:276 ||| ,
there  ||| S:276 E:282 ||| EX
is  ||| S:282 E:285 ||| VBZ
no  ||| S:285 E:288 ||| DT
consensus  ||| S:288 E:298 ||| NN
about  ||| S:298 E:304 ||| IN
the  ||| S:304 E:308 ||| DT
definition  ||| S:308 E:319 ||| NN
or  ||| S:319 E:322 ||| CC
classification  ||| S:322 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
the  ||| S:340 E:344 ||| DT
clinical  ||| S:344 E:353 ||| JJ
patterns  ||| S:353 E:362 ||| NNS
of  ||| S:362 E:365 ||| IN
rosacea ||| S:365 E:372 ||| NN
.  ||| S:372 E:374 ||| .
Initially ||| S:374 E:383 ||| RB
,  ||| S:383 E:385 ||| ,
four  ||| S:385 E:390 ||| CD
stages  ||| S:390 E:397 ||| NNS
were  ||| S:397 E:402 ||| VBD
differentiated  ||| S:402 E:417 ||| NNS
( ||| S:417 E:418 ||| -LRB-
pre-rosacea  ||| S:418 E:430 ||| NNP
then  ||| S:430 E:435 ||| RB
stages  ||| S:435 E:442 ||| VBZ
I  ||| S:442 E:444 ||| PRP
through  ||| S:444 E:452 ||| IN
III ||| S:452 E:455 ||| NNP
) ||| S:455 E:456 ||| -RRB-
,  ||| S:456 E:458 ||| ,
with  ||| S:458 E:463 ||| IN
several  ||| S:463 E:471 ||| JJ
variants  ||| S:471 E:480 ||| NNS
( ||| S:480 E:481 ||| -LRB-
e.g. ||| S:481 E:485 ||| NNP
,  ||| S:485 E:487 ||| ,
persistent  ||| S:487 E:498 ||| JJ
erythema  ||| S:498 E:507 ||| NN
and  ||| S:507 E:511 ||| CC
edema ||| S:511 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
rosacea  ||| S:518 E:526 ||| JJ
conglobata ||| S:526 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
and  ||| S:538 E:542 ||| CC
rosacea  ||| S:542 E:550 ||| JJ
fulminans ||| S:550 E:559 ||| NN
) ||| S:559 E:560 ||| -RRB-
.  ||| S:560 E:562 ||| .
The  ||| S:562 E:566 ||| DT
National  ||| S:566 E:575 ||| NNP
Rosacea  ||| S:575 E:583 ||| NNP
Society  ||| S:583 E:591 ||| NNP
( ||| S:591 E:592 ||| -LRB-
NRS ||| S:592 E:595 ||| NNP
)  ||| S:595 E:597 ||| -RRB-
in  ||| S:597 E:600 ||| IN
the  ||| S:600 E:604 ||| DT
USA  ||| S:604 E:608 ||| NNP
has  ||| S:608 E:612 ||| VBZ
classified  ||| S:612 E:623 ||| VBN
rosacea  ||| S:623 E:631 ||| VBN
into  ||| S:631 E:636 ||| IN
four  ||| S:636 E:641 ||| CD
subtypes  ||| S:641 E:650 ||| NNS
( ||| S:650 E:651 ||| -LRB-
erythematotelangiectatic ||| S:651 E:675 ||| UH
,  ||| S:675 E:677 ||| ,
papulopustular ||| S:677 E:691 ||| NN
,  ||| S:691 E:693 ||| ,
phymatous ||| S:693 E:702 ||| NN
,  ||| S:702 E:704 ||| ,
and  ||| S:704 E:708 ||| CC
ocular ||| S:708 E:714 ||| CD
)  ||| S:714 E:716 ||| -RRB-
and  ||| S:716 E:720 ||| CC
one  ||| S:720 E:724 ||| CD
variant  ||| S:724 E:732 ||| NNS
( ||| S:732 E:733 ||| -LRB-
lupoid  ||| S:733 E:740 ||| NN
or  ||| S:740 E:743 ||| CC
granulomatous  ||| S:743 E:757 ||| JJ
rosacea ||| S:757 E:764 ||| NN
) ||| S:764 E:765 ||| -RRB-
.  ||| S:765 E:767 ||| .
This  ||| S:767 E:772 ||| DT
classification  ||| S:772 E:787 ||| JJ
scheme  ||| S:787 E:794 ||| NN
does  ||| S:794 E:799 ||| VBZ
not  ||| S:799 E:803 ||| RB
mention  ||| S:803 E:811 ||| VB
progression  ||| S:811 E:823 ||| VBN
from  ||| S:823 E:828 ||| IN
one  ||| S:828 E:832 ||| CD
type  ||| S:832 E:837 ||| NN
to  ||| S:837 E:840 ||| TO
another  ||| S:840 E:848 ||| DT
and  ||| S:848 E:852 ||| CC
makes  ||| S:852 E:858 ||| VBZ
no  ||| S:858 E:861 ||| DT
reference  ||| S:861 E:871 ||| NN
to  ||| S:871 E:874 ||| TO
pathophysiological  ||| S:874 E:893 ||| VB
considerations ||| S:893 E:907 ||| NNS
.  ||| S:907 E:909 ||| .
It  ||| S:909 E:912 ||| PRP
uses  ||| S:912 E:917 ||| VBZ
major  ||| S:917 E:923 ||| JJ
and  ||| S:923 E:927 ||| CC
minor  ||| S:927 E:933 ||| JJ
diagnostic  ||| S:933 E:944 ||| JJ
criteria  ||| S:944 E:953 ||| NNS
based  ||| S:953 E:959 ||| VBN
on  ||| S:959 E:962 ||| IN
the  ||| S:962 E:966 ||| DT
physical  ||| S:966 E:975 ||| JJ
findings  ||| S:975 E:984 ||| NNS
and  ||| S:984 E:988 ||| CC
symptoms ||| S:988 E:996 ||| NNS
.  ||| S:996 E:998 ||| .
The  ||| S:998 E:1002 ||| DT
NRS  ||| S:1002 E:1006 ||| NNP
has  ||| S:1006 E:1010 ||| VBZ
also  ||| S:1010 E:1015 ||| RB
developed  ||| S:1015 E:1025 ||| VBN
criteria  ||| S:1025 E:1034 ||| NNS
for  ||| S:1034 E:1038 ||| IN
grading  ||| S:1038 E:1046 ||| JJ
disease  ||| S:1046 E:1054 ||| NN
severity ||| S:1054 E:1062 ||| NN
.  ||| S:1062 E:1064 ||| .
The  ||| S:1064 E:1068 ||| DT
classification  ||| S:1068 E:1083 ||| NN
of  ||| S:1083 E:1086 ||| IN
rosacea  ||| S:1086 E:1094 ||| NN
into  ||| S:1094 E:1099 ||| IN
stages  ||| S:1099 E:1106 ||| NNS
or  ||| S:1106 E:1109 ||| CC
subtypes ||| S:1109 E:1117 ||| NN
,  ||| S:1117 E:1119 ||| ,
without  ||| S:1119 E:1127 ||| IN
considering  ||| S:1127 E:1139 ||| VBG
the  ||| S:1139 E:1143 ||| DT
possibility  ||| S:1143 E:1155 ||| NN
of  ||| S:1155 E:1158 ||| IN
progression  ||| S:1158 E:1170 ||| NN
from  ||| S:1170 E:1175 ||| IN
one  ||| S:1175 E:1179 ||| CD
to  ||| S:1179 E:1182 ||| TO
another ||| S:1182 E:1189 ||| DT
,  ||| S:1189 E:1191 ||| ,
will  ||| S:1191 E:1196 ||| MD
probably  ||| S:1196 E:1205 ||| RB
remain  ||| S:1205 E:1212 ||| VB
controversial  ||| S:1212 E:1226 ||| JJ
until  ||| S:1226 E:1232 ||| IN
additional  ||| S:1232 E:1243 ||| JJ
knowledge  ||| S:1243 E:1253 ||| NN
on  ||| S:1253 E:1256 ||| IN
the  ||| S:1256 E:1260 ||| DT
pathophysiology  ||| S:1260 E:1276 ||| NN
of  ||| S:1276 E:1279 ||| IN
rosacea  ||| S:1279 E:1287 ||| NN
is  ||| S:1287 E:1290 ||| VBZ
obtained ||| S:1290 E:1298 ||| VBN
.  ||| S:1298 E:1300 ||| .
